Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations. research hub

A Phase 2b, Randomised, Double-Blind, Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE).

This study tests a new once-daily inhaled medicine called AZD8630 for adults with asthma. Researchers want to see if different doses can help prevent asthma flare-ups and improve breathing in people whose symptoms are not fully controlled by their usual daily inhalers.